PL2032534T3 - 4-[(3-fluorofenoksy)fenylometylo]piperydyno-metanosulfonian: zastosowanie, proces syntezy i kompozycje farmaceutyczne - Google Patents

4-[(3-fluorofenoksy)fenylometylo]piperydyno-metanosulfonian: zastosowanie, proces syntezy i kompozycje farmaceutyczne

Info

Publication number
PL2032534T3
PL2032534T3 PL07728049T PL07728049T PL2032534T3 PL 2032534 T3 PL2032534 T3 PL 2032534T3 PL 07728049 T PL07728049 T PL 07728049T PL 07728049 T PL07728049 T PL 07728049T PL 2032534 T3 PL2032534 T3 PL 2032534T3
Authority
PL
Poland
Prior art keywords
fluorophenoxy
phenylmethyl
synthesis
pharmaceutical compositions
piperidine
Prior art date
Application number
PL07728049T
Other languages
English (en)
Inventor
Venero Aurelio Orjales
Pestaña Ramón Mosquera
DURÁN Mª CARMEN PUMAR
Avello Antonio Toledo
Mori Gonzalo Canal
Martín Maravillas Bordell
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of PL2032534T3 publication Critical patent/PL2032534T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07728049T 2006-05-12 2007-04-12 4-[(3-fluorofenoksy)fenylometylo]piperydyno-metanosulfonian: zastosowanie, proces syntezy i kompozycje farmaceutyczne PL2032534T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP06380112A EP1854785A1 (en) 2006-05-12 2006-05-12 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
US11/486,350 US20070265306A1 (en) 2006-05-12 2006-07-13 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
PCT/EP2007/053582 WO2007131846A1 (en) 2006-05-12 2007-04-12 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
EP07728049A EP2032534B1 (en) 2006-05-12 2007-04-12 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PL2032534T3 true PL2032534T3 (pl) 2011-08-31

Family

ID=37061190

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07728049T PL2032534T3 (pl) 2006-05-12 2007-04-12 4-[(3-fluorofenoksy)fenylometylo]piperydyno-metanosulfonian: zastosowanie, proces syntezy i kompozycje farmaceutyczne

Country Status (23)

Country Link
US (2) US20070265306A1 (pl)
EP (2) EP1854785A1 (pl)
JP (1) JP2009536962A (pl)
KR (1) KR20090009971A (pl)
CN (1) CN101443312B (pl)
AT (1) ATE501121T1 (pl)
AU (1) AU2007251663B2 (pl)
BR (1) BRPI0710856A2 (pl)
CA (1) CA2651933A1 (pl)
CY (1) CY1111460T1 (pl)
DE (1) DE602007013040D1 (pl)
DK (1) DK2032534T3 (pl)
ES (1) ES2362683T3 (pl)
HR (1) HRP20110333T1 (pl)
MX (1) MX2008014439A (pl)
MY (1) MY148406A (pl)
NO (1) NO20085052L (pl)
NZ (1) NZ572714A (pl)
PL (1) PL2032534T3 (pl)
RS (1) RS51858B (pl)
RU (1) RU2412169C2 (pl)
SI (1) SI2032534T1 (pl)
WO (1) WO2007131846A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854785A1 (en) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
ES2434250T3 (es) 2008-07-24 2013-12-16 Theravance, Inc. Compuestos de 3-(fenoxifenilmetil)pirrolidina
EP2419405A1 (en) * 2009-04-15 2012-02-22 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010273645B2 (en) 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
US9002322B2 (en) * 2011-09-29 2015-04-07 Apple Inc. Authentication with secondary approver
CN104887675B (zh) * 2014-03-05 2018-08-07 江苏恩华药业股份有限公司 [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
AP2006003771A0 (en) * 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
EP1854785A1 (en) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Also Published As

Publication number Publication date
NO20085052L (no) 2008-12-04
EP2032534B1 (en) 2011-03-09
CY1111460T1 (el) 2015-08-05
US20070265306A1 (en) 2007-11-15
RS51858B (sr) 2012-02-29
AU2007251663A1 (en) 2007-11-22
CA2651933A1 (en) 2007-11-22
DE602007013040D1 (de) 2011-04-21
ES2362683T3 (es) 2011-07-11
KR20090009971A (ko) 2009-01-23
BRPI0710856A2 (pt) 2011-05-17
EP1854785A1 (en) 2007-11-14
MX2008014439A (es) 2009-01-21
EP2032534A1 (en) 2009-03-11
HRP20110333T1 (hr) 2011-06-30
CN101443312B (zh) 2011-07-06
MY148406A (en) 2013-04-30
CN101443312A (zh) 2009-05-27
WO2007131846A1 (en) 2007-11-22
JP2009536962A (ja) 2009-10-22
RU2008148941A (ru) 2010-06-20
NZ572714A (en) 2010-08-27
ATE501121T1 (de) 2011-03-15
SI2032534T1 (sl) 2011-06-30
US20100004283A1 (en) 2010-01-07
AU2007251663B2 (en) 2012-04-05
DK2032534T3 (da) 2011-04-26
HK1130053A1 (en) 2009-12-18
RU2412169C2 (ru) 2011-02-20

Similar Documents

Publication Publication Date Title
SI2032534T1 (sl) 4-((3-fluorofenoksi)fenilmetil)piperidin metansulfonat: raba, postopek sintetiziranja in farmacevtske zmesi
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
MX367154B (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2009155121A3 (en) Inhibitors of pi3 kinase
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
UA103617C2 (ru) Производные тиенопиридона как активаторы амр-активированной протеинкиназы (амрк)
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
NO20091185L (no) Piperidinderivater
ZA200806778B (en) N-Hydroxyacrylamide compounds
MY150075A (en) Novel phosphodiesterase inhibitors
WO2007129066A8 (en) 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
NZ601508A (en) Substituted naphthalenyl-pyrimidine compounds and the use thereof in the treatment of cancer
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
NZ598505A (en) 1,2-dihydro-2-oxoquinoline compounds as 5-ht4 receptor ligands
WO2008145524A3 (en) 4,4-disubstituted piperidine derivatives
WO2008087654A3 (en) PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
EA201171229A1 (ru) Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
MX2007010400A (es) Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.